Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Conditions
Interventions
Bimekizumab
Placebo
Locations
77
United States
Ps0013 919
San Diego, California, United States
Ps0013 955
San Diego, California, United States
Ps0013 967
Santa Monica, California, United States
Ps0013 928
Fort Myers, Florida, United States
Ps0013 966
Sandy Springs, Georgia, United States
Ps0013 954
Skokie, Illinois, United States
Start Date
February 5, 2018
Primary Completion Date
December 28, 2018
Completion Date
January 7, 2020
Last Updated
April 15, 2026
NCT07486960
NCT07536529
NCT07295509
NCT07286058
NCT06100744
NCT04402086
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions